The massive YORVIPATH revenue beat and first-ever operating profit mark a fundamental inflection point. The convertible note conversion eliminates a large overhang and the PRV sale adds cash. Watch for YUVIWEL enrollment trajectory and EU regulatory decision in Q4 2026 as the next catalysts. The oncology discontinuation is a minor negative but strategically sound.
Price Chart
Executive Summary
Ascendis Pharma reported Q1 2026 revenue of €247M (up 144% YoY from €101M), driven by YORVIPATH sales of €197M. The company achieved its first-ever operating profit of €25M (vs. a €104M loss in Q1 2025) and a non-IFRS operating profit of €55M. Net profit of €629M included a €679M deferred tax asset recognition; non-IFRS net profit was €18M. Subsequent events include the conversion of $575M convertible notes into 3.6M ordinary shares and a $187.5M PRV sale agreement.
Key Facts
- Q1 2026 total revenue €247M vs €101M YoY (+144%)
- YORVIPATH revenue €197M vs €45M YoY (+341%)
- SKYTROFA revenue €44M vs €51M YoY (-14%)
- Operating profit €25M vs loss of €104M YoY
- Non-IFRS operating profit €55M vs loss of €79M YoY
- Non-IFRS net profit €18M vs loss of €73M YoY
- Net profit €629M includes €679M deferred tax asset recognition
- Cash and equivalents €573M as of March 31, 2026
- Converted all $575M 2.25% convertible notes due 2028 into 3,635,813 ordinary shares on May 6, 2026
- Agreed to sell Rare Pediatric Disease PRV for $187.5M cash
- YUVIWEL launched in U.S. with >60 patient enrollments as of May 1, 2026
- Discontinued internal development of TransCon IL-2/oncology program
Financial Impact
Revenue more than doubled YoY to €247M; operating income swung from -€104M to +€25M; non-IFRS operating profit margin 22.4%; $187.5M PRV sale and $575M convertible note conversion strengthen balance sheet
Risk Factors
- SKYTROFA revenue declining 14% YoY signals potential market share loss
- SG&A expenses rose 44% YoY to €145M, pressuring margins
- Operating cash flow still negative at -€8M despite revenue growth
- Dilution from convertible note conversion adds 3.6M shares
- EU approval for YUVIWEL not guaranteed and could be delayed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-210386 |
| Document: d121855d6k.htm | 0001193125-26-210386 |
| Document: 0001193125-26-210386-index-headers.html | 0001193125-26-210386 |
| Document: 0001193125-26-210386-index.html | 0001193125-26-210386 |
| Document: 0001193125-26-210386.txt | 0001193125-26-210386 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access